Ikarian Capital, LLC Chemo Centryx, Inc. Call Options Transaction History

Ikarian Capital, LLC

$573 Million
Q3 2024

Call Options

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $11 Million - $24.3 Million	-600,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$13.18 - $19.83 $4.99 Million - $7.51 Million	378,800 Added 171.25%	600,000 $10.3 Million
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $203,308 - $1.08 Million	21,200 Added 10.6%	221,200 $2.96 Million
Q1 2021 May 17, 2021	BUY	$49.53 - $68.4 $4.95 Million - $6.84 Million	100,000 Added 100.0%	200,000 $10.2 Million
Q3 2020 Nov 16, 2020	SELL	$46.35 - $61.69 $2.32 Million - $3.08 Million	-50,000 Reduced 33.33%	100,000 $5.48 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $4.91 Million - $7.62 Million	150,000 New	150,000 $6.03 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.